Guidelines

PP01 CRISPR/Cas9 mediated gene correction for the Wiskott-Aldrich syndrome

February 2019
PP02 Donor specific anti-HLA antibodies and allogeneic hematopoietic stem cell transplantation

February 2019
PP03 HLA typing with 11-loci-NGS: benefits in donor selection

February 2019
PP04 Comparison of bone marrow and umbilical cord derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host-disease

February 2019
PP05 Immune cytopenias after allogeneic hematopoietic stem cell transplantation in children

February 2019
PP12 Cognitive impairment, hypoalbuminemia, high CRP level and past history of gastro-intestinal ulcer: 4 markers of frailty which identify older patients with malignant hemopathies who don’t benefit from chemotherapy

February 2019
PP13 Targeting Protein Arginine Methyltransferase PRMT5 in high-risk multiple myeloma: a new treatment strategy?

February 2019
PP14 MRD analysis by next-generation sequencing in multiple myeloma and pediatric acute lymphoblastic leukemia

February 2019
PP15 Development of reticulocytosis through inhibition of terminal erythroid maturation by carfilzomib treatment in multiple myeloma

February 2019
PP16 Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder

February 2019

Top